Related Experiment Video
Updated: Aug 13, 2026

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
Published on: April 5, 2011
High risk of ventricular arrhythmias in patients with nonischemic dilated cardiomyopathy presenting with syncope
Robert S Phang1, David Kang, Hocine Tighiouart
1Tufts-New England Medical Center, Boston, Massachusetts, USA. rphang@gmail.com
Insights
Syncope in nonischemic dilated cardiomyopathy (NIDC) indicates high risk, similar to sustained arrhythmias. Patients with NIDC and syncope may benefit from implantable cardioverter-defibrillator (ICD) therapy.
Area of Science:
- Cardiology
- Electrophysiology
- Heart Failure
Background:
- Syncope in nonischemic dilated cardiomyopathy (NIDC) prognostic significance is unclear.
- Randomized controlled implantable cardioverter-defibrillator (ICD) trials often exclude NIDC patients.
Purpose of the Study:
- Compare outcomes in NIDC patients with syncope versus those with sustained ventricular arrhythmias.
- Evaluate risk factors for arrhythmias and mortality in NIDC patients.
Main Methods:
- Retrospective comparison of 108 NIDC patients with syncope and 71 NIDC patients with sustained ventricular arrhythmias.
- Assessed freedom from ventricular arrhythmias, life-threatening arrhythmias, and all-cause mortality.
- Follow-up duration: 43.5 ± 32.1 months.
Main Results:
- No significant difference in outcomes between syncope and arrhythmia groups.
- Male gender and ICD therapy predicted increased ventricular arrhythmia risk.
- Reduced ejection fraction and older age predicted increased mortality.
Conclusions:
- NIDC patients presenting with syncope represent a high-risk population.
- Event rates in syncope patients are comparable to those with sustained arrhythmias.
- Consideration for ICD therapy is warranted in NIDC patients with syncope.
Abstract:
It is not entirely clear whether the presentation of syncope in patients with nonischemic dilated cardiomyopathy (NIDC) is an ominous prognostic indicator, because randomized controlled implantable cardioverter-defibrillator (ICD) trials generally exclude such patients. This study compared 108 consecutive patients with NIDC presenting with syncope with 71 consecutive patients with NIDC who presented with sustained ventricular arrhythmias, with regard to freedom from any ventricular arrhythmias or life-threatening arrhythmias and all-cause mortality. There was no significant difference between the groups in the 3 outcomes during the follow-up of 43.5 +/- 32.1 months. Male gender and ICD therapy predicted increased risk for any ventricular arrhythmias. A reduced left ventricular ejection fraction and increased age were predictive of increased mortality. In conclusion, patients with NIDC presenting with syncope are a high-risk group, with event rates similar to patients with NIDC presenting with sustained arrhythmias, and should be considered for ICD therapy.
Related Concept Videos
Dysrhythmias IV: Characteristics of Bradyarrhythmias
Cardiomyopathy II: Dilated Cardiomyopathy
Dysrhythmias II: Classification of Tachyarrhythmias
Dysrhythmias V: Evaluating Dysrhythmias
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Mechanism of Cardiac Arrhythmias
